체외진단약(IVD)의 동향과 시장 최신 정보(2023년 11월)

In vitro diagnostic (IVD) testing is getting back to regular business and continues to be a driving force in the practice of medicine. It has gone from helping the physician to diagnose illness to providing the physician with invaluable information on treatments such as precision medicine. COVID-19 testing continues to decline but is still a factor in total revenues for 2023. New products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly changing market picture but one that remains resilient.

“IVD Trends and Market Update: November 2023” by Kalorama Information is the most up-to-date resource on these and other key market trends. Diagnostic test products have never been more important. This report is an update of the market for in vitro diagnostics products from Kalorama's analysts to reflect the latest information as of Q3 2023 with a publication date of November 2023.

There are some growing segments in the market that have attracted industry attention. Among these are Point-of-Care, next-generation sequencing (NGS), cancer testing, and companion diagnostics technologies. Immunochemistry, mass spectrometry. Gene testing and molecular diagnostics are also segments of great market interest, anticipated to be a big part of the future of IVD.

Trends highlighted throughout Q3 2023 include:

• Multiplex testing is proliferating

• Continued interest in adopting AI technologies

Kalorama Information maintains its unwavering dedication to examining the IVD market and its dynamically evolving landscape. The company's excellence in market analysis is attributed to the extensive expertise of its authors and the market research firm's resolute commitment to providing the most precise and up-to-date data.

In “IVD Trends and Market Update: November 2023”, you'll discover out:

• What's Driving Growth in the IVD Market in Q3 and the last half of 2023?

• What Major Trends are Affecting the Market in Q3 and the last half of 2023?

• How Has COVID-19 Impacted and Continued to Impact the Market in Q3 and the last half of 2023?

• What Product Trends and New Developments Will Shape the IVD Market in the last half of 2023?

Table of Contents

Chapter 1: Worldwide IVD Market - October 2023 Update

• IVD Market Demand and Growth
• Figure 1-1: Q3 Segment Performance Commentary, 2023
  • Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2023 ($ million) (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab]; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Microbiology - Mass Spectrometry; Coagulation [PT/INR]; Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
  • Figure 1-2: IVD Segment Performance, Q1 2023 - Q4 2023e ($MN)
  • Figure 1-3: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Total Market Value, 2023 ($MN) Estimated
• COVID-19 Diagnostic Markets
  • Table 1-2: COVID-19 Product Sales, by Segment (Immunoassay [Antigen, Serology], Molecular, Rapid [POC Professional, POC At-Home]), 2023 ($ millions)
• Effect of COVID-19 on Market Segments
  • Table 1-3: IVD Market (excluding and with COVID-19), 2023 ($ millions)
  • Figure 1-4: IVD Market Distribution, by Segment (COVID-19 Assays and Instruments, IVD Market excluding COVID-19 Assays and Instruments), 2023 (%)
  • Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2023 Estimated ($ millions)
  • Table 1-4: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab]; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Coagulation [PT/INR]; Histology/cytology; d-dimer; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth 2022-2023 (%)
  • Figure 1-6: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab]; Hematology - Core Lab; Microbiology [ID/AST]; Microbiology [molecular]; Coagulation [PT/INR]; Histology/cytology; d-dimer; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth 2022-2023 (%)

Chapter 2: Product Trends and New Developments

• Selected New - Q3 2023 - Core IVD Product Launches, Developments and Trends
• Clinical Chemistry
• Flow Cytometry
• Immunoassay
• Mass Spectrometry
• Molecular
• Personalized Medicine
• POC
• Sequencing
• Selected COVID-19 Developments - Q3 2023
  • Figure 2-1: COVID-19 Test Market, by Type (Antigen, Molecular, Serology, Rapid), Q1-Q4 2023 ($ millions)
• Antigen/Antibody
• Molecular

Chapter 3: Top IVD Market Participant Results

• Selected Competitive Leader Updates
  • Figure 3-1: IVD Segment Growth, by Leading Competitors (Abbott Diagnostics, Becton Dickinson, bioMérieux, Danaher, Exact Sciences, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific), Change in Sales, 2022-2023 (%)
  • Figure 3-2: Changes in Market Distribution for IVD Sales, 2020-2023 - Roche and Abbott Battle for #1 Spot
  • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2020-2023 ($ millions)
• Q3 M&A Activity
  • Table 3-1: Q3 2023 Merger and Acquisition Activity
• Abbott Laboratories
  • Table 3-2: Abbott Corporate Summary
• Becton Dickinson and Co
  • Table 3-3: Becton Dickinson Corporate Summary
• bioMérieux SA
  • Table 3-4: bioMérieux Corporate Summary
• Danaher Corporation
  • Table 3-5: Danaher Corporation Summary
• Hologic, Inc.
  • Table 3-6: Hologic Corporate Summary
• QuidelOrtho Corporation
  • Table 3-7: QuidelOrtho Corporate Summary
• Roche Diagnostic
  • Table 3-8: Roche Diagnostic Corporate Summary
• Siemens Healthineers
  • Table 3-9: Siemens Healthineers Corporate Summary
• Sysmex Corporation
  • Table 3-10: Sysmex Corporate Summary
• Thermo Fisher Scientific
  • Table 3-11: Thermo Fisher Scientific Corporate Summary

Chapter 4: New Opportunities

• Multiplex Testing
• Next-Generation Sequencing
• Artificial Intelligence Future Trends
• Disruptive Technologies